We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+13.24%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.44B
AUM Growth
-$133M
Cap. Flow
-$77.2M
Cap. Flow %
-3.16%
Top 10 Hldgs %
50.14%
Holding
73
New
3
Increased
9
Reduced
33
Closed
4

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$44.6M
2
PRME icon
Prime Medicine
PRME
+$39.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.8M
4
REPL icon
Replimune Group
REPL
+$24.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$49.2M
2
PRTA icon
Prothena Corp
PRTA
+$31.9M
3
ONEM
1Life Healthcare
ONEM
+$29.7M
4
SKIN icon
SkinHealth Systems
SKIN
+$24.9M
5
LIVN icon
LivaNova
LIVN
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 99.08%
2 Industrials 0.92%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
26
DELISTED
Ventyx Biosciences
VTYX
$29.3M 1.2%
894,974
-470,026
-34% -$13.9M
ADCT icon
27
ADC Therapeutics
ADCT
$146M
$29.1M 1.19%
7,590,849
+78,820
+1% +$315K
SYK icon
28
Stryker
SYK
$127B
$25.9M 1.06%
105,880
-51,441
-33% -$11.7M
TRDA icon
29
Entrada Therapeutics
TRDA
$273M
$25.1M 1.03%
1,854,108
-100,311
-5% -$1.76M
GRTS
30
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$23.9M 0.98%
6,931,460
-21,300
-0.3% -$60.8K
VERV
31
DELISTED
Verve Therapeutics
VERV
$23.6M 0.97%
1,221,903
-283,223
-19% -$7.5M
CNC icon
32
Centene
CNC
$32B
$23.1M 0.94%
281,260
-1,200
-0.4% -$98K
AUGX
33
DELISTED
Augmedix, Inc. Common Stock
AUGX
$22.4M 0.92%
14,380,327
– –
ALLK
34
DELISTED
Allakos
ALLK
$21.4M 0.88%
2,545,275
– –
ATRA icon
35
Atara Biotherapeutics
ATRA
$92.3M
$20.5M 0.84%
249,710
– –
ELV icon
36
Elevance Health
ELV
$85.5B
$20M 0.82%
38,970
-31,517
-45% -$16M
IMVT icon
37
Immunovant
IMVT
$8.51B
$19.3M 0.79%
+1,088,131
New +$13.7M
SRRK icon
38
Scholar Rock
SRRK
$7.04B
$19M 0.78%
2,095,820
-1,044,206
-33% -$8.38M
ANNX icon
39
Annexon
ANNX
$942M
$18.1M 0.74%
3,503,190
– –
STVN icon
40
Stevanato
STVN
$5.74B
$16.9M 0.69%
942,525
-4,300
-0.5% -$71.3K
ABSI icon
41
Absci
ABSI
$1.49B
$16.9M 0.69%
8,031,094
– –
RAPT
42
DELISTED
RAPT Therapeutics
RAPT
$15.5M 0.64%
98,104
– –
RVMD icon
43
Revolution Medicines
RVMD
$44.6B
$14.9M 0.61%
625,000
– –
STTK icon
44
Shattuck Labs
STTK
$707M
$12.9M 0.53%
5,619,914
– –
MDVL
45
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$10.4M 0.42%
692,090
– –
IONS icon
46
Ionis Pharmaceuticals
IONS
$10.1B
$10.1M 0.41%
266,187
-141,472
-35% -$5.95M
LVTX
47
DELISTED
LAVA Therapeutics
LVTX
$9.86M 0.4%
2,816,196
– –
KLRS
48
Kalaris Therapeutics
KLRS
$95.9M
$9.79M 0.4%
82,955
– –
SNCE
49
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$8.22M 0.34%
990,412
– –
ALXO icon
50
ALX Oncology
ALXO
$277M
$6.85M 0.28%
607,470
-144,627
-19% -$1.62M
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2022 Portfolio in Review

As of Q4 2022, Redmile Group held 73 positions worth $2.44B, down 5.2% from $2.58B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group withdrew a net $77.2M in Q4 2022, closing 4 positions and reducing 33 holdings. Its most notable exit was Prothena Corp, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Prime Medicine worth $41M.

  • Redmile Group's largest Q4 2022 buy was Prime Medicine: 2,209,350 shares worth $41M.
  • Redmile Group added most to Akero Therapeutics in Q4 2022, an estimated $44.6M increase.
  • Redmile Group's biggest Q4 2022 reduction was argenx, cutting an estimated $49.2M.
  • Redmile Group fully exited Prothena Corp in Q4 2022, selling an estimated $31.9M.
  • Redmile Group's ten largest holdings make up 50% of its $2.44B portfolio in Q4 2022.
  • Redmile Group opened 3 new positions and closed 4 in Q4 2022.
  • Redmile Group's portfolio value fell 5.2% quarter-over-quarter to $2.44B.

Based on Redmile Group's 13F filing for Q4 2022, filed 14 Feb 2023.